RVL Pharmaceuticals plc revised sales guidance for the fourth quarter of 2022. For the period, the company expects the sales of UPNEEQ to be $12 to $14 million, representing sequential growth of 20% to 40% compared to the third quarter of 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.00% | 0.00% | -99.97% |
04-12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
03-21 | North American Morning Briefing : Investors -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
-99.97% | 111 | |
+0.82% | 93.19B | |
0.00% | 39.62B | |
-10.35% | 33.78B | |
+64.64% | 26.82B | |
-16.15% | 15.35B | |
-6.98% | 13.13B | |
-11.77% | 11.6B | |
-49.19% | 10.26B | |
+5.92% | 9.43B |
- Stock Market
- Equities
- RVLPQ Stock
- News RVL Pharmaceuticals plc
- RVL Pharmaceuticals plc Revises Sales Guidance for the Fourth Quarter of 2022